title: Raloxifene: a new choice for treating and preventing osteoporosis.
abstract: Selective estrogen receptor modulators (SERMs) are a new class of drugs that provide a new option for addressing the health challenges of postmenopausal women. This review discusses the proposed mechanism of action of SERMs and describes clinical findings on raloxifene, a SERM now available for treating and preventing osteoporosis.
authors.affiliation: Department of Endocrinology, Cleveland Clinic, OH 44195, USA. licataa@ccf.org
authors.forename: A A
authors.initials: AA
authors.lastname: Licata
authors.forename: A V
authors.initials: AV
authors.lastname: Ciaccia
authors.forename: M
authors.initials: M
authors.lastname: Wong
authors.forename: M W
authors.initials: MW
authors.lastname: Draper
mesh_terms: D000368:Aged; D002116:Calcitonin / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy* / Q000517:prevention & control*; D017698:Postmenopause; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D004164:Diphosphonates; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D002116:Calcitonin